MTW vs SBC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MTW presents a stable but fragile financial profile with a Piotroski F-Score of 4/9 and no available Altman Z-Score. While the company is trading at a significant discount to its book value (P/B 0.66) and sales (P/S 0.21), the current price of $13.01 is a premium to both the Graham Number ($9.39) and the growth-based Intrinsic Value ($1.40). A critical disconnect exists between steady revenue growth (13.6%) and a severe collapse in earnings (-88.2%), resulting in an alarmingly thin profit margin of 0.32%. The stock appears to be in a technical downtrend despite a strong 1-year rally, and it currently trades above the analyst target price of $10.50.
SBC presents a paradoxical profile: it is fundamentally undervalued with a P/E of 8.98 and a price below its Graham Number ($5.22), yet it exhibits weak financial health with a Piotroski F-Score of 3/9. While profitability margins are impressive (Gross Margin 73.32%), the company is facing negative revenue growth (-10.90%) and significant insider selling by the CEO. The disconnect between the 'Buy' analyst consensus and the bearish technical/insider trends suggests a high-risk value play with deteriorating fundamentals.
Compare Another Pair
Related Comparisons
MTW vs SBC: Head-to-Head Comparison
This page compares The Manitowoc Company, Inc. (MTW) and SBC Medical Group Holdings Incorporated (SBC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.